Royalty Pharma to Announce First Quarter 2023 Financial Results on May 9, 2023GlobeNewsWire • 04/13/23
Royalty Pharma and PureTech Health Enter Into KarXT Royalty Agreement for Up to $500 MillionGlobeNewsWire • 03/23/23
PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 MillionBusiness Wire • 03/23/23
Royalty Pharma raises FY2023 guidance after $475M Pfizer milestone paymentProactive Investors • 03/15/23
Royalty Pharma: Uncorrelated Yield From Pharmaceutical Product In Uncertain TimesSeeking Alpha • 01/30/23
Royalty Pharma To Announce Fourth Quarter And Full Year 2022 Financial Results On February 15, 2023GlobeNewsWire • 01/18/23
Royalty Pharma: An Attractive Business Model But An Uncertain Outcome For Vertex's CF RoyaltiesSeeking Alpha • 01/10/23
Royalty Pharma Highlights Accomplishments and Provides Business Update at 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/09/23
Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis' Genetic Medicines and Commercial ReadinessGlobeNewsWire • 01/09/23
Ionis and Royalty Pharma enter into royalty agreement for up to $1.1 billion to further advance Ionis' genetic medicines and commercial readinessPRNewsWire • 01/09/23
Royalty Pharma to Present at the J.P. Morgan Healthcare Conference on January 9GlobeNewsWire • 01/04/23